导管导向溶栓后达比加群与华法林治疗急性肺栓塞的比较:多中心随机RE-SPIRE试验结果
RE-SPIRE为前瞻性多中心随机双臂研究,66例高危和中高危急性肺栓塞患者在导管导向溶栓联合减量溶栓后随机接受达比加群150 mg每日两次或华法林治疗6个月。两组平均肺动脉压均显著下降,6个月随访时达比加群组为24 mm Hg(四分位距20.3-29.25 mm Hg),华法林组为23 mm Hg(四分位距20.0-26.3 mm Hg)。深静脉血栓动态变化、部分再通(52.0% vs 73.1%,P=0.15)、完全再通(28.0% vs 19.2%,P=0.56)及大出血事件(0% vs 3.2%,P=1.00)均无统计学差异,但华法林组非大出血事件多于达比加群组(16.1% vs 0%,P=0.02)。
要点
- 导管导向溶栓联合减量溶栓后,达比加群与华法林疗效相当。
- 华法林组非大出血事件16.1%,达比加群组0%(P=0.02)。
- 两组大出血事件0% vs 3.2%(P=1.00),无统计学差异。
核心结论
- 达比加群在疗效上与华法林相当,在术后及长期观察期间所有出血事件的安全性方面优于华法林。
- 作者认为,对于高危和中高危肺栓塞患者,导管导向溶栓联合减量溶栓后可使用达比加群治疗和预防肺栓塞(原文为may be recommended)。
研究设计与样本
- RE-SPIRE为前瞻性、多中心随机双臂研究。
- 在5年期间,66例有症状的高危和中高危肺栓塞患者在血管内机械血栓碎裂术联合减量溶栓(导管导向治疗联合减量溶栓)后48小时内随机分为两组。
- 第一组继续接受达比加群150 mg每日两次治疗6个月;第二组继续接受华法林治疗6个月,国际标准化比值控制在2.0-3.0。
- 两组术后均接受低分子量肝素2天;第一组继续接受低分子量肝素5至7天后转为达比加群150 mg每日两次;第二组接受低分子量肝素联合华法林直至国际标准化比值>2.0后停用肝素。
- 随访期为6个月,63例患者完成研究(达比加群组32例,华法林组31例)。
主要发现
- 两组平均肺动脉压均出现统计学显著下降。
- 术后6个月随访时平均肺动脉压达比加群组为24 mm Hg(四分位距20.3-29.25 mm Hg),华法林组为23 mm Hg(四分位距20.0-26.3 mm Hg)。
- 两组深静脉血栓动态变化无统计学差异。
- 部分再通率达比加群组52.0% vs 华法林组73.1%(P=0.15);完全再通率达比加群组28.0% vs 华法林组19.2%(P=0.56)。
- 根据国际血栓与止血学会标准,大出血事件频率达比加群组0% vs 华法林组3.2%(P=1.00),两组无统计学差异;非大出血事件华法林组16.1% vs 达比加群组0%(P=0.02),华法林组更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombolytic therapy is effective method in the high-risk acute pulmonary embolism (PE) treatment. Reduced-dose thrombolysis (RDT) plus oral anticoagulation therapy is effective and safe method in the moderate and severe PE treatment. It is leading to good early and intermediate-term outcomes. In the RE-COVER and RE-COVER II studies, dabigatran showed similar effectiveness as warfarin in the treatment of acute PE. Dabigatran leads to fewer hemorrhagic complications and is not inferior in efficacy to warfarin in the prevention of PE after mechanical fragmentation and RDT (catheter-directed treatment [CDT]+RDT) in patients with high and intermediate to high PE risk. We sought to evaluate the efficacy and safety (incidence of clinically significant recurrence of venous thromboembolic complications and deaths) during a 6-month course of treatment with dabigatran or warfarin in patients with high and intermediate to high acute PE risk after endovascular mechanical thrombus fragmentation procedure with RDT (CDT+RDT). METHODS: The RE-SPIRE is a prospective, multicenter randomized double-arm study. Over a 5-year period, 66 consecutive patients with symptomatic high and intermediate to high PE risk after endovascular mechanical thrombus fragmentation procedure with RDT (CDT+RDT) were randomized into two groups within the next 48 hours. The first group continued treatment with dabigatran 150 mg twice a day for 6 months; the second group continued treatment with warfarin under the control of international normalized ratio (2.0-3.0) for 6 months. Both groups received low molecular weight heparins for 2 days after surgery. Then, group 1 continued to receive low molecular-weight-heparin for 5 to 7 days, followed by a switch to dabigatran at a dosage of 150 mg two times a day. Group 2 received both low-molecular-weight heparin and warfarin up to an international normalized ratio of >2.0, followed by heparin withdrawal. The follow-up period was 6 months. RESULTS: There were 63 patients who completed the study (32 in the dabigatran group and 31 in the warfarin group). In both groups, there was a statistically significant decrease in the mean pulmonary artery pressure. The mean pulmonary artery pressure at the 6-month follow-up after surgery was 24 mm Hg (interquartile range, 20.3-29.25 mm Hg) in the dabigatran group and 23 mm Hg (interquartile range, 20.0-26.3 mm Hg) in the warfarin group. The groups did not differ statistically in the deep vein thrombosis dynamics. Partial recanalization occurred in 52.0% vs 73.1% in the dabigatran and warfarin groups, respectively (P = .15). Complete recanalization occurred in 28.0% vs 19.2% in the dabigatran and warfarin groups, respectively (P = .56). The groups did not differ in the frequency of major bleeding events according to the International Society for Thrombosis and Hemostasis (0% vs 3.2% in the dabigatran and warfarin groups, respectively; P = 1.00). However, there were more nonmajor bleeding events in the warfarin group than in the dabigatran group (16.1% vs 0%, respectively; P = .02). CONCLUSIONS: The results of the study show that dabigatran is comparable in effectiveness to warfarin. Dabigatran has greater safety in comparison with warfarin in the occurrence of all cases of bleeding in the postoperative and long-term periods. Thus, dabigatran may be recommended for the treatment and prevention of PE after CDT with RDT in patients with high and intermediate to high PE risk.
引用
- Gostev AA, Valiev E, Zeidlits GA, et al. Treatment of acute pulmonary embolism after catheter-directed thrombolysis with dabigatran vs warfarin: Results of a multicenter randomized RE-SPIRE trial. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38346475. doi:10.1016/j.jvsv.2024.101848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。